Home
News
Create
Screeners
Insights
3B BlackBio DX
1,286.
30
-11.90
(-0.92%)
Market Cap
₹1,114.49 Cr
PE Ratio
22.86
Industry
Healthcare Services
Buy
Sell
Company Performance:
1D
-0.92%
1M
-2.94%
6M
-32.02%
1Y
-22.01%
5Y
+45.54%
View Company Insights
Latest news about 3B BlackBio DX
3B BlackBio DX Reports Strong Q2 Results with 37% Revenue Growth and Major Acquisition
Nov 13, 2025
3B BlackBio DX (formerly Kilpest India Limited) announced robust financial results for Q2 FY2026. Standalone revenue increased by 37.1% to 2,791.60 lakhs, while net profit grew 19.9% to 1,494.08 lakhs compared to the previous quarter. The company reported consolidated revenue of 3,890.21 lakhs, which includes the performance of its newly acquired subsidiary, Coris Holding SRL, Belgium. The acquisition was completed on August 29, 2025, incurring one-time expenses of 54.54 lakhs. 3B BlackBio DX operates in agrochemicals and molecular diagnostic kits segments, with a standalone basic EPS of Rs 17.44 for the quarter.
3B BlackBio Dx Reports 18% Revenue Growth in Q1 FY26, Acquires Belgium-Based Coris Bioconcept
Aug 23, 2025
3B BlackBio Dx Limited Reports Strong Q1 Results, Approves Key Board Appointments
Aug 14, 2025
3B BLACKBIO DX Reports Q4 Results: Revenue Up, EBITDA Down, Final Dividend Recommended
May 28, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation